Workshop on clinical trial design in neuromyelitis optica

The aim of the workshop is to better understand the most appropriate choice of comparator to be used in the clinical development of new medicines for the prevention and treatment of neuromyelitis optica.

Regulatory agencies across the world have taken different standpoints on the appropriate choice of comparator for the assessment of the safety and efficacy of new medicines intended for neuromyelitis optica attack prevention.

The EMA has decided to organise this workshop to kick off a wide debate to facilitate medicine development for the benefit of patients with this disease.

Original source


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration